Original Article

Medication Adherence Assessment Among Patients with Type 2 Diabetes Mellitus Treated Polytherapy in Indonesian Community Health Center: A Cross Sectional-Study

Nora Wulandari, Maifitrianti Maifitrianti, Faridlatul Hasanah, Sri Atika, Risa Dini Putri

Faculty of Pharmacy and Science, University of Muhammadiyah Prof. DR. HAMKA Jl Delima II/IV Islamic Center, Malakasari, Duren Sawit, East Jakarta, Indonesia

Submitted : 04-Nov-2019
Revised : 16-Feb-2020
Accepted : 01-Apr-2020
Published : 05-Nov-2020

Background: Type 2 diabetes mellitus (T2DM) is a chronic disease where most of the patients usually need polytherapy. This could affect their medication adherence (MA). However, other complex factors may also associate with MA, which are important to identify. Aim: The purpose of this study was to evaluate the MA of patients with T2DM who received polytherapy and to identify other factors that can affect the MA. Materials and Methods: This was a cross-sectional study conducted in seven community health centers in Jakarta with HbA1C representing their MA level. Poor controlled blood glucose with Hemoglobin A1C (HbA1C) of ≥7% is indicated to have low MA. All characteristics were collected to identify factors that are potentially associated with low MA. The univariate analysis tests were used to analyze factors that potentially associate with low MA. Multiple logistic regression analysis was performed in the factors to find their relationship with low MA. Results: The study obtained 143 patients with a female dominance (67.8%) and mean ± standard deviation (SD) age of 59.53 ± 9.251 years. Approximately 75.5% of the patients had low MA (HbA1C ≥ 7). Univariate analysis found that duration of T2DM significantly (P = 0.047) related to MA, where patients with T2DM of less than or equal to 5 years tended to have low MA. Logistic regression showed that patients with T2DM less than or equal to 5 years (P = 0.015, odds ratio = 1.206, 95% confidence interval = 1.216–8.014) were associated with low MA. Conclusion: Patients with the duration of T2DM less than or equal to 5 years surprisingly were susceptible to have low MA. Low MA was not affected by polytherapy.

Keywords: Medication adherence, polytherapy, type 2 diabetes mellitus

INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder with a maximum number of patients. In 2017, the prevalence of diabetics worldwide was 425 million, and it is estimated that in 2045, people with diabetes will reach 693 million. People with diabetes in Indonesia ranks sixth in the world along with China, India, the United States, Brazil, and Mexico, with an estimated number of people with diabetes of 10 million, and it is expected to increase to 16.7 million people in 2045.

In high-income countries, approximately 7%–12% of all people with diabetes are estimated to have type 1 diabetes, 87%–91% are estimated to have type 2 diabetes, and 1%–3% are estimated to have other types of diabetes.[1] The prevalence of DM is based on a

Address for correspondence: Nora Wulandari, M.Farm., Apt., Jl Delima II/IV Islamic Center, Malakasari, Duren Sawit, East Jakarta 13460, Indonesia. E-mail: wulandari.nora@uhamka.ac.id

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Wulandari N, Maifitrianti M, Hasanah F, Atika S, Dini Putri R. Medication adherence assessment among patients with type 2 diabetes mellitus treated polytherapy in indonesian community health center: A cross sectional-study. J Pharm Bioall Sci 2020;12:S758-62.
Poor glycemic control is a significant contributor to the high rates of morbidity and mortality of patient with type 2 diabetes mellitus (T2DM). One of the key factors related to glycemic control in patient with T2DM is medication adherence (MA). Some studies reported that suboptimal glycemic control is found in patient with low MA. Medication adherence (MA) is commonly used to define the level of compliance to which patients in following the medication prescribed by their health providers. Poor adherence with medication will cause long-term complications that increase morbidity and mortality and increase health costs.

Polypharmacy and/or polytherapy are prevalent in adults with diabetes, especially in individuals with chronic conditions. Polypharmacy and/or polytherapy are one of the factors that influence the adherence of the patients to their medications. Patients who take two drugs or less have a lower risk of lower MA than patients who take more than two drugs. One study in 2017 showed that of the 382 patients with T2DM who received polypharmacy, 57.1% had low adherence. Nevertheless, we hypothesized that other factors could affect MA and associate to the low MA in patients with T2DM in Indonesia.

Therefore, the primary purpose of this study was to evaluate the MA of patients with T2DM who received polytherapy. This study also aimed to identify factors that affect patient’s MA, which is represented by glycemic control of the patients.

**Materials and Methods**

This was a cross-sectional study conducted in seven community health centers (CHC) in Jakarta, Indonesia, from February 2019 to July 2019. The ethical approval for this study was obtained from the ethics committee of the Faculty of Medicine of the University of Indonesia with number: 588/UN2.F1/ETIK/PPM.00.02/2019.

The inclusion criteria of this study included patients with T2DM who were on at least two antidiabetics (ADs) and aged older than or equal to 18 years, of both genders, could speak and understand Indonesian, patients who were on all type of ADs, patients with T2DM with or without comorbidities, patients who were followed up at the site in at least two visits over a minimum period of 6 month. Meanwhile, patients with T2DM who were pregnant, patients who were on dietary control alone, or had intellectual or cognitive impairment as stated in their medical record were excluded from this study.

Data were collected concurrently where potential subjects were screened by the trained research assistants and health worker in the CHC for enrollment eligibility into this study. They were recruited on a monthly gathering of the Chronic Disease Management Program (PROLANIS) in each CHC. Patients who met the requirements were asked to be the study subject by signing a participation agreement or informed consent and given information in advance. A structured questionnaire to obtain factors, which potentially affected MA such as sociodemographic (age, gender, education, and occupation) and clinical characteristics (duration of T2DM, other chronic diseases, complication, number of ADs, and regular daily drug), was given to patients, and then blood was taken to measure HbA1C level by trained health workers who were responsible in each CHC.

The data collected were recapitulated and analyzed. A univariate analysis was carried out to measure the frequency of each characteristic. MA assessment was based on the results of HbA1C examination with a controlled blood glucose (HbA1C) level greater than or equal to 7%, indicated as low MA and vice versa. The Kolmogorov–Smirnov test was performed to measure the normality of the data. A P value >0.05 was considered statistically significant, which means that the data were nonparametric. The univariate analysis with the Mann–Whitney U test was carried out on numerical data that were not normally distributed, whereas for categorical data that were not normally distributed, chi-square test and Fisher’s exact test were used. The data that were significantly related in the univariate analysis were used to perform multivariate tests using multiple regression logistic tests, with the relationship reflected by odds ratios (ORs) (95% confidence intervals [CIs]). A P value of 0.05 was considered statistically significant.
RESULTS

A total of 143 patients with T2DM were enrolled in this study. The sociodemographic and clinical characteristics are presented in Table 1.

Sociodemographic characteristics showed mean ± standard deviation (SD) age of patients as 59.53 ± 9.251 years, with a slightly more dominance in elderly patients (≥60 years) (51.7%) and women (67.8%). Most of the patients were categorized into moderate education (67.8%) and who did not work (78.3%).

On the basis of its clinical characteristics, more than half (69.3%) of the patients had been diagnosed with T2DM for less than or equal to 5 years. Most of (76.2%) patients did not have nor had one other chronic disease such as hypertension, hyperlipidemia, hyperuricemia, angina pectoris, and osteoporosis. As many as 14% of the patients experienced complications in the form of diabetic ulcers and diabetic neuropathy. The use of AD in most patients with T2DM (95.1%) was a combination of two ADs with the use of regular daily drug of up to three drugs.

Of all the characteristics, the duration of T2DM appeared significantly (P = 0.047) related to the level of the MA.

DISCUSSION

We used the HbA\textsubscript{1c} level to represent the MA of the patients, because adherence is the key factor that is significantly affecting glycemic factor of the patients.\cite{10} This study found more than three-quarter (75.5%) of the patients with low MA, which is shown by the HbA\textsubscript{1c} level more than or equal to 7% [Table 1]. This result is

---

Table 1: Characteristics of the patients

| Characteristics          | Total  | Adherent (HbA\textsubscript{1c} < 7%) | Low MA (HbA\textsubscript{1c} ≥ 7%) | P value |
|--------------------------|--------|-------------------------------------|-------------------------------------|---------|
| Total                    | 143 (100.0) | 35 (24.5)                          | 108 (75.5)                          |         |
| Age (years)              |        |                                     |                                     |         |
| Less than 60 years       | 69 (48.3) | 14 (20.3)                           | 55 (79.7)                           |         |
| 60 years or more         | 74 (51.7) | 21 (28.4)                           | 53 (71.6)                           | 0.353*  |
| Mean ± SD = 59.53 ± 9.251|        |                                     |                                     |         |
| Min–max = 37–85          |        |                                     |                                     |         |
| Gender                   |        |                                     |                                     |         |
| Male                     | 46 (32.2) | 12 (26.1)                           | 34 (73.9)                           | 0.920*  |
| Female                   | 97 (67.8) | 23 (23.7)                           | 74 (76.3)                           |         |
| Level of education       |        |                                     |                                     |         |
| Basic                    | 34 (23.8) | 7 (20.6)                            | 27 (79.4)                           | 0.434*  |
| Moderate                 | 96 (67.1) | 23 (24.0)                           | 73 (76.0)                           |         |
| High                     | 13 (9.1)  | 5 (38.5)                            | 8 (61.5)                            |         |
| Occupation               |        |                                     |                                     |         |
| Not working              | 112 (78.3) | 26 (23.2)                           | 86 (76.8)                           | 0.505*  |
| Working                  | 31 (21.7)  | 9 (29.0)                            | 22 (71.0)                           |         |
| Duration of T2DM         |        |                                     |                                     |         |
| 5 years or less          | 88 (61.5) | 27 (30.7)                           | 61 (69.3)                           | 0.047*  |
| More than 5 years        | 55 (38.5) | 8 (14.5)                            | 47 (85.5)                           |         |
| Other chronic diseases   |        |                                     |                                     |         |
| None and one             | 109 (76.2) | 28 (25.7)                           | 81 (74.3)                           | 0.644*  |
| Two and above            | 34 (23.8) | 7 (20.6)                            | 27 (79.4)                           |         |
| Any complication         |        |                                     |                                     |         |
| Yes                      | 20 (14.0)  | 3 (15.0)                            | 17 (85.0)                           | 0.404***|
| No                       | 123 (86.0) | 32 (26.0)                           | 91 (74.0)                           |         |
| Number of AD             |        |                                     |                                     |         |
| Two                      | 136 (95.1) | 34 (25.0)                           | 102 (75.0)                          | 0.522** |
| Three                    | 7 (4.9)    | 1 (14.3)                            | 6 (85.7)                            |         |
| Number of regular daily drugs | |         |                                     |         |
| Up to three              | 98 (68.5)  | 26 (26.5)                           | 7 (73.5)                            | 0.130** |
| Four and more            | 45 (31.5)  | 9 (20.0)                            | 3 (80.0)                            |         |

*Chi-square test, **Mann–Whitney U test, ***Fisher’s exact test
Age did not show a significant relationship to the MA, with slight dominance in the adult patient who had low MA. Meanwhile, female patients were found to have low MA. These observations did not correspond to some studies, which also showed the adult and female patients tended to have low MA. Level of education and working activity did not show any significance in the number of patients with low MA, which is also similar to a previous study. 

This study did not find the number of medications (AD or other) taken daily that affected MA; hence, it did not show an association with low MA. Other studies also found the insufficiency of association between number of regular daily drugs and low MA. Seven combinations of AD were used by the patients in the study, which were insulin and acarbose; metformin and acarbose; metformin and glipalamide; metformin and glicludone; metformin, glicludone, and acarbose; metformin and glimepiride; and metformin, glimepiride, and acarbose. Of all these combinations, the combination of metformin and glimepiride reportedly had most patients with low MA. This result was not in accordance with previous studies, which reported that the combination was more effective in glycemic control which should also reflect their MA.

This study underlined a significant association between the duration of T2DM and MA [Table 2]. Patients with T2DM duration less than 5 years tend to have low MA \( (P = 0.015, \ OR = 1.206, \ 95\% \ CI = 1.216–8.014) \). Another study had a similar finding, whereas there were other studies too, which found a lack of association between both. 

Limitations and strengths: Though this study measured the MA based on the reliable data of HbA\(_\text{le}^\text{c}\), assessment, it could not identify the reason for low MA. However, this method is fast and convenient at a study site where the HbA\(_\text{le}^\text{c}\) is regularly assessed. This study provided a better result on MA in glycemic control perspective in Indonesia, especially Jakarta, due to the larger sample that covered seven community health centers in Jakarta. Although our results did not show a relationship between polytherapy and low MA, health-care professionals must continue to pay attention to patients receiving polytherapy and/or polypharmacy. This is because it is one of the risk factors that affect MA. In this study, we found that the duration of T2DM was associated with a low MA, which unexpectedly showed that patients who had T2DM for less than or equal to 5 years were more at risk of having a low MA; therefore, further investigation of the factors affecting MA was needed in new patients with T2DM for less than 5 years.

### Conclusion

This study shows a low increase in MA in patients with T2DM in Jakarta. This is important to be addressed by supporting the growing awareness of adherence to antidiabetic among patients, for example, by giving regular education to the patients. Although the polytherapy was found to be unrelated to MA, a surprising finding showed that patients who experienced T2DM less than or equal to five years were prone to have low MA. Health care providers must continue to strive to improve MA in T2DM patients. This can be done by providing counseling and/or any kind of education to patients at each visit and correctly assessing the MA. In addition, improving the relationship between patients and health workers by providing self-management guidelines, which can be done by patients, can also improve glycemic control and health outcomes. As the implication of polytherapy on MA in patients with chronic disease was an intended problem we wanted to identify in our study, we think pharmacy services such as therapeutic management are needed to optimize drug use therefore the use of drugs can be more efficient. Pharmacist and other health workers can work together to not prescribe or stop unnecessary drugs or drugs that cause problems.

### Table 2: Logistic regression test results on factors influencing medication adherence

| Characteristics                  | Low MA (OR, 95% CI)* | P value |
|----------------------------------|----------------------|---------|
| Age (years)                      | 1.907 (0.789–4.606)  | 0.152   |
| Gender                           | 0.927 (0.352–2.437)  | 0.877   |
| Level of education               | 0.575 (0.268–1.236)  | 0.156   |
| Occupation                       | 1.807 (0.604–5.410)  | 0.290   |
| Other chronic diseases           | 1.586 (0.462–5.448)  | 0.464   |
| Number of AD                     | 2.455 (0.237–25.375) | 0.451   |
| Duration of T2DM                 | 3.173 (1.206–8.014)  | 0.015   |
| Number of regular daily drugs    | 1.181 (0.387–3.602)  | 0.743   |

*Multiple logistic regression
Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. International Diabetes Federation. IDF Diabetes Atlas Eighth Edition 2017. Karuranga S, Fernandes J da R, Huang Y, Malanda B, editors. IDF Diabetes Atlas, 8th edition. International Diabetes Federation, United Kingdom; 2017. 1-150.
2. Ministry of Health of Republic of Indonesia. Hasil Utama Rikesdas [Internet]. Rikesdas. Jakarta; 2018. [Last accessed: 2019 September 30]. Available from: http://kesmas.kemkes.go.id/ke150d418dcd98f00/files/Hasil-riskesdas-2018_1274.pdf.
3. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 2012;35:1279-84.
4. Waari G, Mutai J, Gikunju J. Medication adherence and factors associated with poor adherence among type 2 diabetes mellitus patients on follow-up at Kenyatta National Hospital, Kenya. Pan Afr Med J 2018;29:82.
5. Basu S, Garg S, Sharma N, Singh MM, Garg S. Adherence to self-care practices, glycemic status and influencing factors in diabetes patients in a tertiary care hospital in Delhi. World J Diabetes 2018;9:72-9.
6. García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013;4:175-94.
7. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence 2016;10:1299-307.
8. Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012;18:527-39.
9. KopruLu F, Bader RJK, Hassan NAGM, Abdelkareem AR, Mahmood DA. Evaluation of adherence to diabetic treatment in northern region of United Arab Emirates. Trop J Pharm Res 2014;13:989-95.
10. Lee CS, Tan JHM, Sankari U, Koh YLE, Tan NC. Assessing oral medication adherence among patients with type 2 diabetes mellitus treated with polytherapy in a developed Asian community: a cross-sectional study. BMJ Open 2017;7:e016317.
11. American Diabetes Association. American Diabetes Association: pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care 2018;41:64-76.
12. Sunjaya AP, Sunjaya AF. Glycated hemoglobin targets and glycemic control: link with lipid, uric acid and kidney profile. Diabetes Metab Syndr 2018;12:743-8.
13. Quah JH, Liu YP, Luo N, How CH, Tay EG. Younger adult type 2 diabetic patients have poorer glycaemic control: a cross-sectional study in a primary care setting in Singapore. BMC Endocr Disord 2013;13:18.
14. Perwitasari DA, Urbayatun S. Treatment adherence and quality of life in diabetes mellitus patients in Indonesia. SAGE Open 2016;6:1-7.
15. Bakhli B, Alwaibbi M, Alqahtani N, Alhawassi T, Alshammarri TM, Mahmoud M, et al. Oral antidiabetic medication adherence and glycaemic control among patients with type 2 diabetes mellitus: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open 2019;9:e029280.
16. Thommanduru P, Lekhanth A, Revanth A, Gopinath C, Babu SC. Effect of polypharmacy on medication adherence in patients with type 2 diabetes mellitus. Indian J Pharm Pract 2015;8:126-32.
17. Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, et al. Efficacy of glimepiride/metformin fixed-dose combination vs metformin up titration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: a randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig 2014;5:701-8.
18. Haghighatpanah M, Nejad ASM, Haghighatpanah M, Thunga G, Mallayasamy S. Factors that correlate with poor glycemic control in type 2 diabetes mellitus patients with complications. Osong Public Health Res Perspect 2018;9:167-74.
19. Aminde LN, Tindong M, Ngwasiri CA, Aminde JA, Njim T, Fondong AA, et al. Adherence to antidiabetic medication and factors associated with non-adherence among patients with type-2 diabetes mellitus in two regional hospitals in Cameroon. BMC Endocr Disord 2019;19:35.
20. Marinho FS, Moram CBM, Rodrigues PC, Leite NC, Salles GF, Cardoso CRL. Treatment adherence and its associated factors in patients with type 2 diabetes: results from the Rio De Janeiro type 2 diabetes cohort study. J Diabetes Res 2018;2018:1-8.